(Q40653405)

22 September 2017

title

Enhancement of the therapeutic effectiveness of methotrexate and protection of normal proliferating tissues with purines and pyrimidines (English)

1 reference

https://api.crossref.org/works/10.1016/0009-2797(77)90147-8

16 June 2022

1 reference

K. R. Harrap

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A302148

16 June 2022

G. A. Taylor

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A302148

16 June 2022

G. P. Browman

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A302148

16 June 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=302148

16 June 2022

publication date

1 July 1977

1 reference

full work available at URL

22 September 2017

https://api.elsevier.com/content/article/PII:0009279777901478?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0009-2797(77)90147-8

https://api.elsevier.com/content/article/PII:0009279777901478?httpAccept=text/plain

16 June 2022

1 reference

https://api.crossref.org/works/10.1016/0009-2797(77)90147-8

Chemico-biological Interactions

16 June 2022

published in

1 reference

22 September 2017

volume

18

1 reference

22 September 2017

issue

1

1 reference

22 September 2017

page(s)

119-128

1 reference

Recent advances in the chemotherapy of metastatic osteogenic sarcoma

22 September 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1016/0009-2797(77)90147-8

Eradication Of Leukaemic Cells (L1210) by Methotrexate and Methotrexate Plus Citrovorum Factor

16 June 2022

5

1 reference

https://api.crossref.org/works/10.1016/0009-2797(77)90147-8

Methotrexate toxicity: Correlation with duration of administration, plasma levels, dose and excretion pattern

16 June 2022

6

1 reference

https://api.crossref.org/works/10.1016/0009-2797(77)90147-8

New approaches to cancer chemotherapy with methotrexate

16 June 2022

8

1 reference

https://api.crossref.org/works/10.1016/0009-2797(77)90147-8

Consequences of methotrexate inhibition of purine biosynthesis in L5178Y cells

16 June 2022

15

1 reference

https://api.crossref.org/works/10.1016/0009-2797(77)90147-8

Factors determining cell sensitivity to methotrexate: Studies of folate and deoxyribonucleoside triphosphate pools in five mammalian cell lines

16 June 2022

16

1 reference

https://api.crossref.org/works/10.1016/0009-2797(77)90147-8

Some Observations on the Reversibility of Methotrexate Toxicity in Normal Proliferating Tissues2

16 June 2022

17

1 reference

https://api.crossref.org/works/10.1016/0009-2797(77)90147-8

The reversal of methotrexate toxicity by thymidine with maintenance of antitumour effects

16 June 2022

18

1 reference

https://api.crossref.org/works/10.1016/0009-2797(77)90147-8

Methotrexate-thymidine treatment of murine leukemia

16 June 2022

19

1 reference

https://api.crossref.org/works/10.1016/0009-2797(77)90147-8

16 June 2022

Identifiers

1 reference

22 September 2017

1 reference